Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SAN DIEGO, March 07, 2016 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the 28th Annual Roth Conference at 3:30 pm PST on Monday, March 14, 2016, at the Ritz Carlton in Dana Point, CA.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The company’s clinical-stage pipeline includes two product candidates: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers and wet AMD through a collaboration with Santen Pharmaceutical Company Ltd., and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
